Page 759 - ONLINE PROCEEDING BOOK WSAVA 2017
P. 759

WSVA7-0117 ONCOLOGY/ONCOSURGERY
A PILOT, UNCONTROLLED STUDY OF POSTSURGICAL TREATMENT WITH AUTOLOGOUS DENDRITIC CELL-BASED IMMUNOLOGIC THERAPY IN 17 DOGS WITH MAMMARY ADENOCARCINOMA
L. Grammel1
1Justus von Liebig University, Veterinary College, Gießen, Germany
Introduction
The treatment with monocyte derived dendritic cells is
a new concept in the immunologic treatment of dogs with adenocarcinomas of the mamma. A study group of 17 bitches of different breeds with a medium age of 9.1 years at the onset of the disease is presented here.
Objectives
17 dogs were treated with a mastectomy of the affected mammary complexes. Already during surgery, a sample
of the tumour tissue was saved and stored deep-
frozen. After a con rmed patho-histological diagnosis of adenocarcinoma, the bitches underwent an immunologic treatment course of 3 autologous monocyte-derived dendritic cell treatments in a monthly interval. The treatment was performed intradermally around the surgical site.
WSVA7-0041 ONCOLOGY/ONCOSURGERY
CLINICAL AND IMMUNOLOGICAL ANTI-CANCER EFFECTS OF CANINE IL-15 THERAPY COMBINED WITH METRONOMIC CYCLOPHOSPHAMIDE IN DOGS WITH CANCER
S.K. Kim1, D.J. Shin1, S.H. Lee2, Y.K. Lee3, M.Y. Kang3, D. Yu4, C. Park5
1Kongju National University, Department of Companion and Laboratory Animal Science, Yesan, Republic of Korea
2Kongju National University, Department of Integrated Life Science and Technology, Yesan, Republic of Korea 3Chonnam National University Hwasun Hospital, Research Center for Cancer Immunotherapy, Hwasun, Republic of Korea
4Chonnam National University, Dapartment of Veterinary Internal Medicine- College of Veterinary Medicine, Gwang-ju, Republic of Korea
5Chonbuk National University, Dapartment of Veterinary Internal Medicine- College of Veterinary Medicine, Jeonju, Republic of Korea
Introduction
Interleukin-15 (IL-15) is a pleiotropic cytokine that plays a pivotal role in both innate and adaptive immunity. IL-15 is also a promising cytokine for treating cancer. Despite a growing interest in the use of IL-15 as an immunotherapeutic agent, it has not been reported the immunological and clinical effects of IL-15 on cancers in dogs.
Objectives
In this study, we generated a recombinant canine IL-15 (rcIL-15), and determined its biological effects on immune effector cells, and con rmed its safety in vivo. After
then, clinical and immunomodulatory effects of rcIL-15 in combination with metronomic cyclophosphamide were evaluated in canine patients with various tumor types.
Methods
To determine the safety and immunologic effects, rcIL-15 was injected intravenously in doses of 20 μg/kg daily for 8 days and monitored for 32 days. Treatment outcomes in dogs with cancers were evaluated in a prospective clinical trial. Low dose of cyclophosphamide (15 mg/m2, PO, SID) was continuously administrated for 7 weeks. From day 14 after administration of cyclophosphamide, rcIL-15 (20 μg/kg daily) was injected intravenously for 8 days.
Methods
For each treatment course, a fresh whole blood
sample from the patient was processed by gradient centrifugation and an adherence step to derive a population of monocytes. These monocytes were cultivated with speci c cytokines to derive autologous dendritic cells. After 6 days in culture, the dendritic cells were primed with tumour lysate. On day 7, the antigen- presenting dendritic cells were harvested, re-suspended and injected intradermal.
Results
11 of 17 dogs are still living. Of the deceased dogs, only 3 died of progressive disease. The censored median survival is 1041 days, the censored medium survival is 1045 days post primary treatment.
Conclusions
The autologous treatment with primed dendritic cells of dogs with adenocarcinoma of the mamma is a promising postsurgical treatment option which should be considered as an alternative to chemotherapeutical interventions. This pilot study shows interesting results which should be followed up.
An Urban Experience
759


































































































   757   758   759   760   761